Algipharma AS
🇳🇴Norway
- Country
- 🇳🇴Norway
- Ownership
- Private
- Established
- 2006-08-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.algipharma.com
A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis
Phase 2
Terminated
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: OligoG DPI
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- AlgiPharma AS
- Target Recruit Count
- 15
- Registration Number
- NCT03822455
- Locations
- 🇦🇺
John Hunter Hospital, Newcastle, New South Wales, Australia
A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis
Phase 2
Withdrawn
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: OligoG Dry powder for inhalation
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- AlgiPharma AS
- Registration Number
- NCT03698448
- Locations
- 🇩🇪
CF Zentrum Köln, Universitätskrankenhaus Köln, Cologne, Germany
A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection
Phase 2
Completed
- Conditions
- Burkholderia InfectionCystic Fibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- AlgiPharma AS
- Target Recruit Count
- 15
- Registration Number
- NCT02453789
- Locations
- 🇩🇪
Pneumologische Praxis Pasing, Münich, Münich-Pasing, Germany
🇩🇪Charité Universitätsmedizin Berlin, Berlin, Germany
A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- AlgiPharma AS
- Target Recruit Count
- 65
- Registration Number
- NCT02157922
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇪CF Zentrum Köln, Universitätskrankenhaus Köln, Cologne, Germany
🇩🇪Medizinische Klinik I, Pneumologie, Uniklinik, Frankfurt, Germany
A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- AlgiPharma AS
- Target Recruit Count
- 26
- Registration Number
- NCT01465529
- Locations
- 🇮🇪
Beaumont Hospital, Dublin, Ireland
🇮🇪University College Hospital Galway, Galway, Ireland
🇬🇧Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis
- First Posted Date
- 2009-09-02
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- AlgiPharma AS
- Target Recruit Count
- 26
- Registration Number
- NCT00970346
© Copyright 2025. All Rights Reserved by MedPath